Favorable response to erlotinib in a lung adenocarcinoma with both EGFR exon-19 deletion and K-ras G13D mutations

CN, Lee;HY, Chen;HE, LiuLee;HY, Chen;HE, LiuCN2026-05-212026-05-212010https://203.71.86.71/handle/123456789/24378藥學系計畫報告Favorable response to erlotinib in a lung adenocarcinoma with both EGFR exon-19 deletion and K-ras G13D mutationsreport